InventisBio's Potential Best-in-Class TYK2 Inhibitor Advances to Late-Stage

InventisBio has initiated a Phase III clinical trial for its novel TYK2 allosteric inhibitor nomelcitinib (D-2570) in moderate-to-severe plaque psoriasis. The multicentre, randomised, double-blind, placebo-controlled study (n=390) will evaluate efficacy and safety, with the primary endpoint being the percentage of patients achieving ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) at week 16. Nomelcitinib selectively targets TYK2’s JH2 domain, inhibiting cytokine signalling and inflammation.

In Phase II trials, nomelcitinib performed favourable: 75% to 77.5% of patients achieved PASI 90 at 12 weeks (vs 5% placebo), rivalling biologic drugs. Globally, 23 TYK2 inhibitors are in development, including 12 allosteric types. Nomelcitinib joins five others in Phase III, positioning InventisBio to compete with leaders like BMS's deucravacitinib (the only approved TYK2 inhibitor), Takeda's zasocitinib and Hansoh Pharma's HS-10374.

Subscribe to our newsletter
A weekly newsletter curated for industry professionals. Join thousands of fellow subscribers for free
Subscribe for Free
Daily News
AbbVie Immunology Duo Skyrizi/Rinvoq Delivers USD 11.6b in H1'25
2025-08-02
BMS H1'25 Revenue hits USD 23.5b Driven by Opdivo's USD 4.8b
2025-08-02
Hrain's CD19 CAR-T Therapy Approved as China's Fourth for Lymphoma
2025-08-02
Sanofi Reports EUR 19.9b H1 Revenue With Dupixent Topping EUR 7b
2025-08-02
AllianThera Partners with Dr. Falk Pharma on Novel UC Drug
2025-08-01
Latest Report
From Reliance to Defiance: A Decade-Long Panorama of China's Innovative Drug Transactions
Details